GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » Cyclically Adjusted PS Ratio

Natco Pharma (BOM:524816) Cyclically Adjusted PS Ratio : 5.34 (As of Jun. 04, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma Cyclically Adjusted PS Ratio?

As of today (2025-06-04), Natco Pharma's current share price is ₹861.40. Natco Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₹161.28. Natco Pharma's Cyclically Adjusted PS Ratio for today is 5.34.

The historical rank and industry rank for Natco Pharma's Cyclically Adjusted PS Ratio or its related term are showing as below:

BOM:524816' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.5   Med: 6.97   Max: 11.48
Current: 5.45

During the past years, Natco Pharma's highest Cyclically Adjusted PS Ratio was 11.48. The lowest was 4.50. And the median was 6.97.

BOM:524816's Cyclically Adjusted PS Ratio is ranked worse than
80.22% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.155 vs BOM:524816: 5.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Natco Pharma's adjusted revenue per share data for the three months ended in Mar. 2025 was ₹68.167. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ₹161.28 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Natco Pharma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Natco Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma Cyclically Adjusted PS Ratio Chart

Natco Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.36 7.09 4.67 6.78 4.95

Natco Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.78 7.84 9.09 8.81 4.95

Competitive Comparison of Natco Pharma's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Natco Pharma's Cyclically Adjusted PS Ratio falls into.


;
;

Natco Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Natco Pharma's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=861.40/161.28
=5.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Natco Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Natco Pharma's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=68.167/157.5517*157.5517
=68.167

Current CPI (Mar. 2025) = 157.5517.

Natco Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 13.063 99.841 20.614
201509 14.615 101.753 22.629
201512 15.871 102.901 24.300
201603 24.179 102.518 37.159
201606 18.690 105.961 27.790
201609 26.164 105.961 38.903
201612 38.319 105.196 57.390
201703 32.246 105.196 48.295
201706 25.413 107.109 37.381
201709 24.253 109.021 35.049
201712 31.664 109.404 45.599
201803 41.501 109.786 59.557
201806 29.125 111.317 41.222
201809 29.364 115.142 40.180
201812 30.271 115.142 41.421
201903 23.147 118.202 30.853
201906 26.987 120.880 35.174
201909 26.652 123.175 34.090
201912 26.440 126.235 32.999
202003 23.394 124.705 29.556
202006 30.877 127.000 38.305
202009 43.954 130.118 53.221
202012 19.431 130.889 23.389
202103 -1.673 131.771 -2.000
202106 22.484 134.084 26.419
202109 20.685 135.847 23.990
202112 30.674 138.161 34.979
202203 30.542 138.822 34.663
202206 48.454 142.347 53.629
202209 23.659 144.661 25.767
202212 26.957 145.763 29.137
202303 48.598 146.865 52.134
202306 63.117 150.280 66.171
202309 57.580 151.492 59.883
202312 42.370 152.924 43.652
202403 59.641 153.035 61.401
202406 76.069 155.789 76.930
202409 76.541 157.882 76.381
202412 26.525 158.323 26.396
202503 68.167 157.552 68.167

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Natco Pharma  (BOM:524816) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Natco Pharma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Natco Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Natco Pharma Business Description

Traded in Other Exchanges
Address
Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.

Natco Pharma Headlines

No Headlines